Vogl,NY on How to Ask Good Questions at Medical Meetings

Vogl, NY

S. Vogl

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

ASCO® 2023 Summary: "GI Key Studies Including PROSPECT, HERIZON-BTC-…

Insights from 2023 ASCO® Annual Meeting

R. Kim, R. Mehta

GI Cancers: Hot Topics in 2024

Yale Cancer Center

J. Lacy

ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunot…

2024 ESMO Annual Meeting Insights Hub

L. Rimassa

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

GRACE

A. Goodman, A. Jeong, S. Rajeeve

Y90 Radioembolization for Locally Advanced HCC

UCLA Health

S. Padia

Endocrine Adverse Events From Checkpoint Inhibitors

Yale Cancer Center

K. Herold

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

ESMO 2024 Summary: Highlights in HCC

2024 ESMO Annual Meeting Insights Hub

R. Kim, T. Biachi

Updates in Combination Therapy for HCC

Yale Cancer Center

S. Stein

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

ESMO 2024 Insights: TACE ± Lenvatinib + Pembro for Int-Stage HCC - P…

2024 ESMO Annual Meeting Insights Hub

J. Llovet

ASCO® 2024 Summary: "Experts Discuss Key Studies in HCC and BTC"

2024 ASCO® Annual Meeting Insights Hub

R. Kim, T. Biachi

2023 AASLD Guidance for HCC

University of Texas Southwestern Medical Center

A. Singal

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

Year in Review: Hepatobiliary Cancers

Moffitt Cancer Center

R. Kim, T. Biachi

ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab + Durvaluma…

2024 ESMO Annual Meeting Insights Hub

L. Rimassa

Current Approach to Frontline Systemic Therapy for Advanced Hepatoce…

Lionel Kankeu Fonkoua

ASCO® GI 2024 Summary: "HCC Key Studies Including EMERALD-1 & IMbrav…

Insights from 2024 ASCO® GI Annual Meeting

R. Kim, T. Biachi